Evidence map›Paper›PMID 42244994›Full record

ArticleTheranostics2026

ecPICK: A deep learning-enabled spatial diagnostic platform for direct ecDNA identification and clinical prognosis across pan-cancer histopathology.

Xue-Ting Zhen, Zhen Yang, Lu-Ning Qin, Yun-Long Zhao, Lu Chen, Ming Gao, Tao Sun, Heng Zhang

Abstract read
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xue-Ting ZhenTianjin Union Medical Center, The First Affiliated Hospital of Nankai University, College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.
Zhen YangDepartment of Oncology, The Institute of Translational Medicine, Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, State Key Laboratory of Neurology and Oncology Drug Development, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin 300121, China.
Lu-Ning QinTianjin Union Medical Center, The First Affiliated Hospital of Nankai University, College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.
Yun-Long ZhaoTianjin Union Medical Center, The First Affiliated Hospital of Nankai University, College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.
Lu ChenDepartment of Hepatobiliary Cancer, Liver cancer research center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Ming GaoDepartment of Thyroid and Breast Surgery, The Institute of Translational Medicine, Tianjin Cancer Institute of Integrative Traditional Chinese and Western Medicine, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University, Tianjin 300121, China.
Tao SunTianjin Union Medical Center, The First Affiliated Hospital of Nankai University, College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.
Heng ZhangTianjin Union Medical Center, The First Affiliated Hospital of Nankai University, College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Extrachromosomal DNA (ecDNA) is an important driver of oncogene amplification and drug resistance; however, its clinical assessment is constrained by the high costs of sequencing and lack of spatial resolution in conventional assays. Thus, a cost-effective, clinically translatable platform is required for ecDNA quantification and localization using routine pathological samples. Methods: We developed the deep learning framework ecPICK that identifies and localizes ecDNA in routine H&E-stained whole-slide images. The model was trained and tested using 4,280 images representing 20 different cancers. Its diagnostic efficacy was evaluated by area under the curve (AUC) analysis, and its spatial accuracy was verified via fluorescent in situ hybridization (FISH). In addition, the tumor microenvironment associated with ecDNA was examined by combining ecPICK with spatial transcriptomics. Results: ecPICK showed strong agreement with FISH-validated ecDNA levels (R Conclusions: ecPICK provides a scalable, budget-conscious platform for ecDNA mapping without the need for high-cost sequencing. By revealing the spatial remodeling of the tumor landscape, it represents a powerful tool for rapid patient stratification and novel insights into ecDNA-mediated malignant progression.

Indexed as

Deep LearningExtrachromosomal DNANeoplasmsBiomarkers, TumorHumansIn Situ Hybridization, FluorescencePrognosisTumor MicroenvironmentBiomarkers, TumorExtrachromosomal DNAartificial intelligencedeep learningdigital pathologyecDNAspatial diagnosticsspatial transcriptomicstumor microenvironment

Identifiers

PMID42244994
PMCPMC13232621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.